Jeff Frelick - 17 Jan 2024 Form 4 Insider Report for Bone Biologics Corp (BBLG)

Role
Chief Executive Officer
Signature
/s/ Jeffrey Frelick
Issuer symbol
BBLG
Transactions as of
17 Jan 2024
Transactions value $
$0
Form type
4
Filing time
19 Jan 2024, 17:22:54 UTC
Previous filing
12 Sep 2023
Next filing
21 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BBLG Common Stock 2.15K 17 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBLG Employee Stock Option Award $0 +25K $0.00 25K 17 Jan 2024 Common Stock 25K $3.61 Direct F1
holding BBLG Employee Stock Option 173 17 Jan 2024 Common Stock 173 $9,540.00 Direct F2
holding BBLG Employee Stock Option 44 17 Jan 2024 Common Stock 44 $12,300.00 Direct F2
holding BBLG Employee Stock Option 208 17 Jan 2024 Common Stock 208 $892.80 Direct F2
holding BBLG Employee Stock Option 157 17 Jan 2024 Common Stock 157 $57.60 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.
F2 This option is fully vested as of the date of this report.